Looks like you’re on the UK site. Choose another location to see content specific to your location
Merck launches new CellASIC ONIX2 microfluidic system
Merck has launched a new system that provides precise control and manipulation of cell culture environments for advanced live cell imaging applications.
The CellASIC ONIX2 microfluidic system is used to optimise laboratory microscopes for live cell imaging, allowing users to more effectively perform in-depth analysis of cellular mechanisms and behaviour in a live environment.
Offering constant, stable imaging conditions while preserving the health of cells, the all-in-one system includes a controller to maintain environmental conditions, as well as application-specific microfluidic plates and intuitive software.
This lets researchers monitor cellular responses to environmental changes such as media, stimulants, temperature and gas, and track individual cells over time. The use of microfluidic technology and a small cell culture chamber allows changes to be carried out faster and more consistently compared with traditional cell culture methods.
With these tools, scientists can deepen their understanding of cell functions, while accelerating the development of innovative new therapies.
Jason Apter, head of research solutions strategic marketing and innovation for life science at Merck, said: "Live cell imaging is an essential instrument for researchers, allowing them to deepen their understanding of biological function, accelerating life-saving or life-extending therapies."
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard